

13
~~16~~ 18. The truncated MCP-2 of claim ~~15~~, wherein the truncated MCP-2 has the amino acid sequence of SEQ ID NO: 5.

13
~~17~~ 19. The truncated MCP-2 of claim ~~15~~, wherein the truncated MCP-2 lacks NH₂-terminal amino acids corresponding to amino acid residue 1 of naturally-occurring MCP-2 (SEQ ID NO: 2).

13
~~18~~ 20. The truncated MCP-2 of claim ~~15~~, wherein the truncated MCP-2 lacks NH₂-terminal amino acids corresponding to amino acid residues 1-2 of naturally-occurring MCP-2 (SEQ ID NO: 2).

13
B1 ~~19~~ 21. The truncated MCP-2 of claim ~~15~~, wherein the truncated MCP-2 lacks NH₂-terminal amino acids corresponding to amino acid residues 1-3 of naturally-occurring MCP-2 (SEQ ID NO: 2).

13
~~20~~ 22. The truncated MCP-2 of claim ~~15~~, wherein the truncated MCP-2 lacks NH₂-terminal amino acids corresponding to amino acid residues 1-4 of naturally-occurring MCP-2 (SEQ ID NO: 2).

13 20
~~21~~ 23. The truncated MCP-2 of any one of claims ~~15~~ through ~~22~~, wherein the truncated MCP-2 is in glycosylated form.

20
~~22~~ 24. A pharmaceutical composition comprising a truncated MCP-2 of any one of claims ~~15~~ through ~~22~~ and one or more pharmaceutically acceptable carriers and/or excipients.

13 20 21
~~23~~ 25. A pharmaceutical composition comprising a truncated MCP-2 of claim ~~23~~ and one or more pharmaceutically acceptable carriers and/or excipients.